ROTTERDAM, NETHERLANDS – March 27, 2024 – Van Herk Investments, a leading investor in life sciences, and Sairopa B.V., a pioneer in the development of innovative cancer immunotherapies, announce that Van Herk Investments has completed the purchase of the minority position in shares of Sairopa previously held by Novartis.
This transition comes after Novartis’ acquisition of Chinook Therapeutics, Inc. in 2023, aimed at bolstering its renal portfolio, which prompted the divestment of non-renal assets linked to the acquisition, including its shares in Sairopa.
In April 2021, backed by the robust support and investment from Van Herk Investments, Sairopa acquired a portfolio of non-renal therapeutic antibodies from Chinook Therapeutics, Inc., propelling the company into the forefront of cancer immunotherapy research and development. The acquisition, including assets originally developed by BioNovion/Aduro Biotech, has since marked a significant milestone in Sairopa’s pursuit of novel cancer treatments.
Since integrating the oncology assets into its pipeline, Sairopa has made significant advancements in preclinical and clinical development programs. This progress underscores the company’s dedication to unlocking new possibilities for cancer patients worldwide through innovative immune-modulating treatments.
With the steady support of Van Herk Investments and the diligent efforts of its research and development teams, Sairopa is well-positioned to continue making valuable contributions to the field of oncology, bringing hope to patients and families affected by cancer.
About Sairopa
Sairopa B.V. is a clinical-stage company that develops novel treatments for cancer by modulating the patient’s immune system. With a portfolio of therapeutic antibodies developed from groundbreaking research and proprietary platforms, Sairopa aims to lead the way in the development of effective cancer immunotherapies. For more information about Sairopa, please visit www.sairopa.com.
About Van Herk Group
The Rotterdam-based Van Herk Group holds a portfolio of investments in real estate, energy and life sciences. The group supports innovative companies in their quest to discover and develop transformative healthcare solutions. Van Herk Investments’ engagement with Sairopa is a testament to its mission to foster advancements in science that can significantly improve human health.
Forward-Looking Statements
This press release contains forward-looking statements, including statements related to the clinical and therapeutic potential of Sairopa’s pipeline, future plans and potential for clinical and commercial success. These forward-looking statements are based on the companies’ current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties.
Contact Information:
Sairopa B.V.
CIC Stationsplein 45
Unit A4.004
3013 AK Rotterdam
The Netherlands
info@sairopa.com